Clinical Trial

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Study acronym: HUTONG
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese participants with nAMD.
Protocol Amendment History 45 amendments
This ClinicalTrials.gov record has been amended 45 times since 2022-09-29; most recent amendment 2026-07-04.
Status change: Not Yet Recruiting → Recruiting 2024-04-10
Status change: Recruiting → Not Yet Recruiting 2022-11-08
Trial Details
NCT Number NCT05562947
Lead Sponsor Hoffmann-La Roche
Conditions Neovascular Age-related Macular Degeneration, nAMD
Enrollment 68 participants
Start Date 2024-06-17
Primary Completion 2027-07-27 (estimated)
Study Completion 2029-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-04